{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:29:12Z","timestamp":1762918152621,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s13730-020-00507-4","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T21:03:23Z","timestamp":1595019803000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of tocilizumab in amyloid a nephropathy associated with Sweet syndrome: a case report and literature review"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3773-9744","authenticated-orcid":false,"given":"D.","family":"Giannese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Moriconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"Bonadio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Elefante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F.","family":"Egidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cupisti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"issue":"23","key":"507_CR1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lackmann","year":"2007","unstructured":"Lackmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Eng J Med. 2007;356(23):2361\u201371.","journal-title":"N Eng J Med."},{"key":"507_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10020-018-0047-0","volume":"24","author":"GH Sack Jr","year":"2018","unstructured":"Sack GH Jr. Serum amyloid\u2014a review. Mol Med. 2018;24:46.","journal-title":"Mol Med"},{"issue":"1","key":"507_CR3","first-page":"54","volume":"110","author":"R Scapioni","year":"2018","unstructured":"Scapioni R, et al. Renal involvement in autoinflammatory diseases and inflammasome-mediated chronic kidney damage. Clin and Exp Rheum. 2018;110(1):54\u201360.","journal-title":"Clin and Exp Rheum"},{"key":"507_CR4","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1073\/pnas.74.9.4025","volume":"74","author":"EP Benditt","year":"1977","unstructured":"Benditt EP, et al. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci USA. 1977;74:4025\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"507_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4254\/wjh.v10.i1.1","volume":"10","author":"JA Del Campo","year":"2018","unstructured":"Del Campo JA, et al. Role of inflammatory response in liver diseases: therapeutic strategies. World J Hepatol. 2018;10(1):1\u20137.","journal-title":"World J Hepatol"},{"issue":"9275","key":"507_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","volume":"358","author":"JD Gillmore","year":"2001","unstructured":"Gillmore JD, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358(9275):24\u20139.","journal-title":"Lancet"},{"key":"507_CR7","first-page":"3155","volume":"32","author":"T Kuroda","year":"2012","unstructured":"Kuroda T, et al. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in reactive amyloidosis associated with rheumatoid arthritis. Amyloid. 2012;32:3155\u201362.","journal-title":"Amyloid"},{"issue":"Suppl. 110","key":"507_CR8","first-page":"S54","volume":"36","author":"R Scarpioni","year":"2018","unstructured":"Scarpioni R, et al. Renal involvement in autoinflammatory diseases and inflammasome-mediated chronic kidney damage. Clin Exp Rheumatol. 2018;36(Suppl. 110):S54\u2013S60.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"507_CR9","first-page":"502","volume":"37","author":"O Di Munno","year":"2019","unstructured":"Di Munno O, et al. The effect of biologic agents on bone homeostasis in chronic inflammatory rheumatic diseases. Clin Exp Rheumatol. 2019;37(3):502\u20137 (Epub 2018 Nov 19).","journal-title":"Clin Exp Rheumatol."},{"issue":"10","key":"507_CR10","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Toshio","year":"2014","unstructured":"Toshio T, et al. IL-6 in Inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. https:\/\/doi.org\/10.1101\/cshperspect.a016295.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"507_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.bbrc.2003.12.096","volume":"314","author":"K Hagihara","year":"2004","unstructured":"Hagihara K, et al. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314:363\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"507_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1365-141.1993.tb03083.x","volume":"84","author":"MA Reuss-Borst","year":"1993","unstructured":"Reuss-Borst MA, et al. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol. 1993;84(2):356\u20138. https:\/\/doi.org\/10.1111\/j.1365-141.1993.tb03083.x.","journal-title":"Br J Haematol"},{"issue":"3","key":"507_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1365-2141.1994.tb08340.x","volume":"87","author":"A Loraas","year":"1994","unstructured":"Loraas A, et al. Cytokine response pattern in Sweets syndrome associated with myelodysplasia. Br J Haematol. 1994;87(3):669.","journal-title":"Br J Haematol"},{"issue":"4","key":"507_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/BF02982648","volume":"77","author":"H Hattori","year":"2003","unstructured":"Hattori H, et al. Sweets syndrome associated with recurrent fever in a patient with trisomy 8 myelodysplastic syndrome. Int J Hematol. 2003;77(4):383\u20136. https:\/\/doi.org\/10.1007\/BF02982648.","journal-title":"Int J Hematol"},{"issue":"1","key":"507_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13256-017-1317-0","volume":"11","author":"Y Takano","year":"2017","unstructured":"Takano Y, et al. Serum cytokine profile in pediatric Sweets Syndrome: a case report. J Med Case Rep. 2017;11(1):178. https:\/\/doi.org\/10.1186\/s13256-017-1317-0.","journal-title":"J Med Case Rep"},{"issue":"1","key":"507_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1871530317666171120150329","volume":"18","author":"NS Yarla","year":"2018","unstructured":"Yarla NS, et al. Effects of olive oil on TNF-\u03b1 and IL-6 in humans: implication in obesity and frailty. Endocr Metab Immune Disord Drug Targets. 2018;18(1):63\u201374. https:\/\/doi.org\/10.2174\/1871530317666171120150329.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"16","key":"507_CR17","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1161\/01.CIR.99.16.2219.c","volume":"99","author":"JP Bastard","year":"1999","unstructured":"Bastard JP, et al. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation. 1999;99(16):2219\u201322. https:\/\/doi.org\/10.1161\/01.CIR.99.16.2219.c.","journal-title":"Circulation"},{"issue":"15","key":"507_CR18","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1111\/bph.12713","volume":"171","author":"D Qu","year":"2014","unstructured":"Qu D, et al. IL-6 in diabetes and cardiovascular complications. Br J Pharmacol. 2014;171(15):3595\u2013603. https:\/\/doi.org\/10.1111\/bph.12713.","journal-title":"Br J Pharmacol"},{"key":"507_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/DDDT.S150580","volume":"13","author":"M Biggioggero","year":"2019","unstructured":"Biggioggero M, et al. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2019;13:57\u201370.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"507_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3109\/0886022X.2013.773913","volume":"35","author":"MD Redondo-Pach\u00f3n","year":"2013","unstructured":"Redondo-Pach\u00f3n MD, et al. Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet\u2019s disease. Ren Fail. 2013;35(4):547\u201350.","journal-title":"Ren Fail"},{"issue":"4","key":"507_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/13506129.2011.613962","volume":"18","author":"C Magro-Checa","year":"2011","unstructured":"Magro-Checa C, et al. Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis. Amyloid. 2011;18(4):235\u20139.","journal-title":"Amyloid"},{"key":"507_CR22","doi-asserted-by":"crossref","unstructured":"Yamada Y, et al. Tocilizumab\u00a0histologically improved AA renal amyloidosis in a patient with multicentric Castleman\u00a0disease: a case report\u2029. Clin Nephrol 2018. PMID\u00a029701172","DOI":"10.5414\/CN109273"},{"key":"507_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s12882-017-0799-8","volume":"18","author":"A Yamagata","year":"2017","unstructured":"Yamagata A, et al. Rapid clinical improvement of amyloid A amyloidosis following treatment with tocilizumab despite persisting amyloid deposition: a case report. BMC Nephrol. 2017;18:377.","journal-title":"BMC Nephrol"},{"key":"507_CR24","doi-asserted-by":"crossref","unstructured":"Iijima T, et al. Tocilizumab\u00a0improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis. Mod Rheumatol 2013","DOI":"10.1007\/s10165-013-0854-7"},{"key":"507_CR25","unstructured":"Serelis J, et al. Remission of nephrotic syndrome due to AA-amyloidosis, complicating familiar Mediterranean fever, with\u00a0tocilizumab. Clin Exp Rheumatol 2015."},{"key":"507_CR26","doi-asserted-by":"crossref","unstructured":"Yamada S, et al. Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis. CEN Case Rep 2014","DOI":"10.1007\/s13730-014-0127-0"},{"key":"507_CR27","unstructured":"Hasegawa S, et al. [Case report; a case of rheumatoid arthritis with renal amyloidosis and nephrotic syndrome effectively treated with\u00a0tocilizumab]. Nihon Naika Gakkai Zasshi 2011"},{"issue":"1","key":"507_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/13506129.2017.1301420","volume":"24","author":"H Uda","year":"2017","unstructured":"Uda H, et al. Tocilizumab postpones the start of hemodialysis compared to conventional or al treatment in amyloid A amyloidosis patients with advanced renal insufficiency by suppressing serum SAA levels. Amyloid. 2017;24(1):62\u20133.","journal-title":"Amyloid"},{"key":"507_CR29","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.2169\/internalmedicine.54.4183","volume":"54","author":"T Iijima","year":"2015","unstructured":"Iijima T, et al. Tocilizumab for AA Amyloidosis after treatment of multicentric Castleman disease with steroids, chemotherapy and rituximab for Over 20 Years. Intern Med. 2015;54:3215\u20139.","journal-title":"Intern Med"},{"issue":"1","key":"507_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12882-018-1065-4","volume":"19","author":"M Matsunami","year":"2018","unstructured":"Matsunami M, et al. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome. BMC Nephrol. 2018;19(1):263.","journal-title":"BMC Nephrol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00507-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-020-00507-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00507-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T23:50:42Z","timestamp":1626479442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-020-00507-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["507"],"URL":"https:\/\/doi.org\/10.1007\/s13730-020-00507-4","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2020,7,17]]},"assertion":[{"value":"22 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}